Перспективы применения хондропротекторов для лечения легочной патологии

Актуальность. Комплексные механизмы действия хондроитина сульфата (ХС) и глюкозамина сульфата (ГС) на молекулярном уровне позволяют утверждать, что соответствующие препараты применимы далеко за пределами хондропротекции. Ингибирование провоспалительных механизмов (NF-κB, активация толл-рецепторов, повышение уровней цитокинов, дегрануляция тучных клеток и др.) посредством ХС и ГС обусловливает перспективы их применения для торможения процессов воспаления в дыхательных путях и аллергических процессов, а также для усиления эффектов глюкокортикоидов.
Цель: систематизация данных об эффектах хондроитина сульфата и глюкозамина сульфата на патофизиологические процессы при легочной патологии.
Материал и методы. Методами теории топологического анализа текстов проведен интеллектуальный анализ 1273 публикаций по фундаментальным и клиническим исследованиям взаимосвязей ХС и ГС с функцией легких. Поиск статей осуществляли по ключевому запросу “(glucosamine OR chondroitin) AND (lung OR lungs OR pulmonary OR pulmonology)” в базе биомедицинских публикаций Pubmed/MEDLINE. В результате было выделено 59 информативных биомедицинских терминов.
Результаты. Хемопротеомное исследование ХС и ГС показало, что их прием способствует повышению экспрессии 19 противоопухолевых белков и снижению экспрессии 25 провоспалительных белков, вовлеченных в функционирование легких. ХС и ГС могут использоваться в комплексной терапии инфекционных заболеваний легких, при фибротических изменениях дыхательных путей, а также позволяют снизить риск опухолевых заболеваний легких.
Заключение. Результаты анализа указывают на перспективность применения ХС и ГС при ряде опухолевых заболеваний легких и высокую безопасность препаратов на основе фармацевтических стандартизированных форм ХС и ГС с точки зрения функции легких.

1. Reginato A.M., Riera H., Vera M., et al. Osteoarthritis in Latin America: study of demographic and clinical characteristics in 3040 patients. J Clin Rheumatol. 2015; 21 (8): 391–7. https://doi.org/10.1097/RHU.0000000000000281.

2. Торшин И.Ю., Лила А.М., Лиманова О.А., Громова О.А. Перспективы применения хондроитина сульфата и глюкозамина сульфата при остеоартрите в сочетании с патологией почек и мочевыделительной системы. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (1): 23–34. https://doi.org/10.17749/2070-4909.2020.13.1.23-34.

3. Торшин И.Ю., Лила А.М., Наумов А.В. и др. Перспективы персонификации профилактики и терапии остеоартрита на основании анализа коморбидного фона, генетических полиморфизмов и микроэлементного статуса. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (1): 28–39. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.077.

4. Mendy A., Apewokin S., Wells A.A., Morrow A.L. Factors associated with hospitalization and disease severity in a racially and ethnically diverse population of COVID-19 patients. medRxiv. 2020; Jun 27, 2020. https://doi.org/10.1101/2020.06.25.20137323.

5. Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337–50. https://doi.org/10.1016/j.semarthrit.2019.04.008.

6. Торшин И.Ю., Громова О.А., Чучалин А.Г., Журавлев Ю.И. Хемореактомный скрининг воздействия фармакологических препаратов на SARS-CoV-2 и виром человека как информационная основа для принятия решений по фармакотерапии COVID-19. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (2): 191–211. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.078.

7. Shannon J.M., McCormick-Shannon K., Burhans M.S., et al. Chondroitin sulfate proteoglycans are required for lung growth and morphogenesis in vitro. Am J Physiol Lung Cell Mol Physiol. 2003; 285 (6): L1323–36. https://doi.org/10.1152/ajplung.00226.2003.

8. Souza-Fernandes A.B., Pelosi P., Rocco P.R. Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease. Crit Care. 2006; 10 (6): 237. https://doi.org/10.1186/cc5069.

9. Negrini D., Passi A., Moriondo A. The role of proteoglycans in pulmonary edema development. Intensive Care Med. 2008; 34 (4): 610– 8. https://doi.org/10.1007/s00134-007-0962-y.

10. Torshin I.Yu., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019; 29 (4): 654–67. https://doi.org/10.1134/S1054661819040175.

11. Torshin I.Y. Optimal dictionaries of the final information on the basis of the solvability criterion and their applications in bioinformatics. Pattern Recognit Image Anal. 2013; 23: 319–27. https://doi.org/10.1134/S1054661813020156.

12. Torshin I.Yu., Rudakov K.V. On the theoretical basis of the metric analysis of poorly formalized problems of recognition and classification. Pattern Recognit Image Anal. 2015; 25 (4): 577–87.

13. Wu Y.L., Kou Y.R., Ou H.L., et al. Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010; 635 (1-3): 219–26. https://doi.org/10.1016/j.ejphar.2010.02.044.

14. Chuang K.H., Peng Y.C., Chien H.Y., et al. Attenuation of LPSinduced lung inflammation by glucosamine in rats. Am J Respir Cell Mol Biol. 2013; 49 (6): 1110–9. https://doi.org/10.1165/rcmb.2013-0022OC.

15. Rao N.V., Kennedy T.P., Rao G., et al. Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis. 1990; 142 (2): 407–12. https://doi.org/10.1164/ajrccm/142.2.407.

16. Kantor E.D., Lampe J.W., Navarro S.L., et al. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation. J Altern Complement Med. 2014; 20 (6): 479– 85. https://doi.org/10.1089/acm.2013.0323.

17. Wang D., DuBois R.N. Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila). 2013; 6 (6): 507–10. https://doi.org/10.1158/1940-6207.CAPR-13-0153.

18. Thompson H.L., Schulman E.S., Metcalfe D.D. Identification of chondroitin sulfate E in human lung mast cells. J Immunol. 1988; 140 (8): 2708–13.

19. Stevens R.L., Fox C.C., Lichtenstein L.M., Austen K.F. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA. 1988; 85 (7): 2284–7. https://doi.org/10.1073/pnas.85.7.2284.

20. Jung A.Y., Heo M.J., Kim Y.H. Glucosamine has an antiallergic effect in mice with allergic asthma and rhinitis. Int Forum Allergy Rhinol. 2017; 7 (8): 763–9. https://doi.org/10.1002/alr.21967.

21. Chung M.J., Park J.K., Park Y.I. Anti-inflammatory effects of lowmolecular weight chitosan oligosaccharides in IgE-antigen complexstimulated RBL-2H3 cells and asthma model mice. Int Immunopharmacol. 2012; 12 (2): 453–9. https://doi.org/10.1016/j.intimp.2011.12.027.

22. Pouvelle B., Meyer P., Robert C., et al. Chondroitin-4-sulfate impairs in vitro and in vivo cytoadherence of Plasmodium falciparum infected erythrocytes. Mol Med. 1997; 3 (8): 508–18.

23. Bastos M.F., Albrecht L., Kozlowski E.O., et al. Fucosylated chondroitin sulfate inhibits Plasmodium falciparum cytoadhesion and merozoite invasion. Antimicrob Agents Chemother. 2014; 58 (4): 1862– 71. https://doi.org/10.1128/AAC.00686-13.

24. Bachman H. Prolonged use of oxytetracycline hydrochloride with glucosamine in twenty-five patients for nonspecific complications associated with pulmonary tuberculosis. Dis Chest. 1960; 38: 303–4. https://doi.org/10.1378/chest.38.3.303.

25. Rodrigues S., da Costa A.M.R., Flórez-Fernández N., et al. Inhalable spray-dried chondroitin sulphate microparticles: effect of different solvents on particle properties and drug activity. Polymers (Basel). 2020; 12 (2): 425. https://doi.org/10.3390/polym12020425.

26. Hwang J.S., Kim K.H., Park J., et al. Glucosamine improves survival in a mouse model of sepsis and attenuates sepsis-induced lung injury and inflammation. J Biol Chem. 2019; 294 (2): 608–22. https://doi.org/10.1074/jbc.RA118.004638.

27. Vishniakova L.A., Reztsova Iu.V. A method for preventing experimental pneumococcal infection. Zh Mikrobiol Epidemiol Immunobiol. 1997; 2: 20–3.

28. Bensadoun E.S., Burke A.K., Hogg J.C., Roberts C.R. Proteoglycan deposition in pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 154 (6 Pt. 1): 1819–28. https://doi.org/10.1164/ajrccm.154.6.8970376.

29. Yoshida A., Hiramatsu M., Hatakeyama K., Minami N. Elevation of glucosamine 6-phosphate synthetase activity in bleomycin-induced pulmonary fibrosis in hamsters. J Antibiot (Tokyo). 1982; 35 (7): 882–5. https://doi.org/10.7164/antibiotics.35.882.

30. Kai Y., Yoneyama H., Yoshikawa M., et al. Chondroitin sulfate in tissue remodeling: therapeutic implications for pulmonary fibrosis. Respir Investig. 2021; 59 (5): 576–88. https://doi.org/10.1016/j.resinv.2021.05.012.

31. Mizumoto S., Sugahara K. Glycosaminoglycans are functional ligands for receptor for advanced glycation end-products in tumors. FEBS J. 2013; 280 (10): 2462–70. https://doi.org/10.1111/febs.12156.

32. Ju Y., Yu A., Sun X., et al. Glucosamine, a naturally occurring amino monosaccharide, inhibits A549 and H446 cell proliferation by blocking G1/S transition. Mol Med Rep. 2013; 8 (3): 794–8. https://doi.org/10.3892/mmr.2013.1584.

33. Song K.H., Kang J.H., Woo J.K., et al. The novel IGF-IR/Aktdependent anticancer activities of glucosamine. BMC Cancer. 2014; 14: 31. https://doi.org/10.1186/1471-2407-14-31.

34. Liang Y., Xu W., Liu S., et al. N-acetyl-glucosamine sensitizes nonsmall cell lung cancer cells to TRAIL-induced apoptosis by activating death receptor 5. Cell Physiol Biochem. 2018; 45 (5): 2054–70. https://doi.org/10.1159/000488042.

35. Brezillon S., Zeltz C., Schneider L., et al. Lumican inhibits B16F1 melanoma cell lung metastasis. J Physiol Pharmacol. 2009; 60 (Suppl. 4): 15–22.

36. Borsig L., Wang L., Cavalcante M.C., et al. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem. 2007; 282 (20): 14984–91. https://doi.org/10.1074/jbc.M610560200.

37. Zhang J.S., Imai T., Otagiri M. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. Arch Toxicol. 2000; 74 (6): 300–7. https://doi.org/10.1007/s002040000124.

38. Lei X., Ma N., Liang Y., et al. Glucosamine protects against radiationinduced lung injury via inhibition of epithelial-mesenchymal transition. J Cell Mol Med. 2020; 24 (18): 11018–23. https://doi.org/10.1111/jcmm.15662.

39. Brasky T.M., Lampe J.W., Slatore C.G., White E. Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Causes Control. 2011; 22 (9): 1333–42. https://doi.org/10.1007/s10552-011-9806-8.

40. Li G., Zhang X., Liu Y., et al. Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study. Eur Respir J. 2021: 2101399. https://doi.org/10.1183/13993003.01399-2021.

41. Navarro S.L., White E., Kantor E.D., et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015; 10 (2): e0117534. https://doi.org/10.1371/journal.pone.0117534.

42. Wang Q., Zhang Y., Zhang T., et al. Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer. Onco Targets Ther. 2015; 8: 1971–7. https://doi.org/10.2147/OTT.S85478.

43. Peng Z., Gong Y., Liang X. Role of FAT1 in health and disease. Oncol Lett. 2021; 21 (5): 398. https://doi.org/10.3892/ol.2021.12659.

44. Foxler D.E., Bridge K.S., James V., et al. The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity. Nat Cell Biol. 2012; 14 (2): 201–8. https://doi.org/10.1038/ncb2424.

45. Zeng X., Wang H., He D., et al. LIMD1 increases the sensitivity of lung adenocarcinoma cells to cisplatin via the GADD45α/p38 MAPK signaling pathway. Front Oncol. 2020; 10: 969. https://doi.org/10.3389/fonc.2020.00969.

46. Cui Y., Liang S., Zhang S., et al. ABCA8 is regulated by miR-374b-5p and inhibits proliferation and metastasis of hepatocellular carcinoma through the ERK/ZEB1 pathway. J Exp Clin Cancer Res. 2020; 39 (1): 90. https://doi.org/10.1186/s13046-020-01591-1.

47. Gong M., Li Y., Ye X., et al. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation. Cell Commun Signal. 2020; 18 (1): 98. https://doi.org/10.1186/s12964-020-00568-z.

48. Salimi U., Menden H.L., Mabry S.M., et al. Angiopoietin-1 protects against endotoxin-induced neonatal lung injury and alveolar simplification in mice. Pediatr Res. 2021; May 12. https://doi.org/10.1038/s41390-021-01544-0.

49. Michael I.P., Orebrand M., Lima M., et al. Angiopoietin-1 deficiency increases tumor metastasis in mice. BMC Cancer. 2017; 17 (1): 539. https://doi.org/10.1186/s12885-017-3531-y.

50. Yuan L., Zhang X., Yang M., et al. Airway epithelial integrin β4 suppresses allergic inflammation by decreasing CCL17 production. Clin Sci (Lond). 2020; 134 (13): 1735–49. https://doi.org/10.1042/CS20191188.

51. Liu X., Wu S., Xia Y., et al. Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011; 301 (6): G992–1003. https://doi.org/10.1152/ajpgi.00080.2011.

52. Khairnar V., Duhan V., Maney S.K., et al. CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production. Nat Commun. 2015; 6: 6217. https://doi.org/10.1038/ncomms7217.

53. Arcone R., Arpaia G., Ruoppolo M., et al. Structural characterization of a biologically active human lipocortin 1 expressed in Escherichia coli. Eur J Biochem. 1993; 211 (1-2): 347–55. https://doi.org/10.1111/j.1432-1033.1993.tb19904.x.

54. Leoni G., Neumann P.A., Kamaly N., et al. Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair. J Clin Invest. 2015; 125 (3): 1215–27. https://doi.org/10.1172/JCI76693.

55. Easter M., Garth J., Harris E.S., et al. Fibroblast growth factor receptor 4 deficiency mediates airway inflammation in the adult healthy lung? Front Med (Lausanne). 2020; 7: 317. https://doi.org/10.3389/fmed.2020.00317.

56. Anderson B.D., Nakamura T., Russell S.J., Peng K.W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004; 64 (14): 4919–26. https://doi.org/10.1158/0008-5472.CAN-04-0884.

57. Grumelli S., Lu B., Peterson L., et al. CD46 protects against chronic obstructive pulmonary disease. PLoS One. 2011; 6 (5): e18785. https://doi.org/10.1371/journal.pone.0018785.

58. Szabo R., Netzel-Arnett S., Hobson J.P., et al. Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity. Biochem J. 2005; 390 (Pt. 1): 231–42. https://doi.org/10.1042/BJ20050299.

59. Akiyama M., Takeda S., Kokame K., et al. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci USA. 2009; 106 (46): 19274–9. https://doi.org/10.1073/pnas.0909755106.

60. Denorme F., Kraft P., Pareyn I., et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017; 12 (6): e0179258. https://doi.org/10.1371/journal.pone.0179258.

61. Cao Z., Bhella D., Lindsay J.G. Reconstitution of the mitochondrial PrxIII antioxidant defence pathway: general properties and factors affecting PrxIII activity and oligomeric state. J Mol Biol. 2007; 372 (4): 1022–33. https://doi.org/10.1016/j.jmb.2007.07.018.

62. Zhen W.Q., Xie Z.Z., Wang X., et al. Influences of PON1 on airway inflammation and remodeling in bronchial asthma. J Cell Biochem. 2018; 119 (1): 793–805. https://doi.org/10.1002/jcb.26242.

63. Amatullah H., Maron-Gutierrez T., Shan Y., et al. Protective function of DJ-1/PARK7 in lipopolysaccharide and ventilator-induced acute lung injury. Redox Biol. 2021; 38: 101796. https://doi.org/10.1016/j.redox.2020.101796.

64. Richarme G., Liu C., Mihoub M., et al. Guanine glycation repair by DJ-1/Park7 and its bacterial homologs. Science. 2017; 357 (6347): 208–11. https://doi.org/10.1126/science.aag1095.

65. Jang B.C., Sung S.H., Park J.G., et al. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem. 2007; 282 (38): 27622–32. https://doi.org/10.1074/jbc.M610778200.

66. Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Современная ревматология. 2018; 12 (2): 36–43. https://doi.org/10.14412/1996-7012-2018-2-36-43.

67. Song P., Xie Z., Wu Y., et al. Protein kinase czeta-dependent LKB1 serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells. J Biol Chem. 2008; 283 (18): 12446–55. https://doi.org/10.1074/jbc.M708208200.

68. Cheng X., Ma Y., Moore M., et al. Phosphorylation and activation of cAMP-dependent protein kinase by phosphoinositide-dependent protein kinase. Proc Natl Acad Sci USA. 1998; 95 (17): 9849–54. https://doi.org/10.1073/pnas.95.17.9849.

69. Reimold A.M., Iwakoshi N.N., Manis J., et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001; 412 (6844): 300–7. https://doi.org/10.1038/35085509.

70. Ronkina N., Menon M.B., Schwermann J., et al. MAPKAP kinases MK2 and MK3 in inflammation: complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol. 2010; 80 (12): 1915–20. https://doi.org/10.1016/j.bcp.2010.06.021.

71. Fan C., Rajasekaran D., Syed M.A., et al. MIF intersubunit disulfide mutant antagonist supports activation of CD74 by endogenous MIF trimer at physiologic concentrations. Proc Natl Acad Sci USA. 2013; 110 (27): 10994–9. https://doi.org/10.1073/pnas.1221817110.

72. Aung G., Niyonsaba F., Ushio H., et al. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology. 2011; 132 (4): 527–39. https://doi.org/10.1111/j.1365-2567.2010.03395.x.

73. Keegan A.D., Nelms K., White M., et al. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell. 1994; 76 (5): 811–20. https://doi.org/10.1016/0092-8674(94)90356-5.

74. Harashima S., Horiuchi T., Wang Y., et al. Sorting nexin 19 regulates the number of dense core vesicles in pancreatic β-cells. J Diabetes Investig. 2012; 3 (1): 52–61. https://doi.org/10.1111/j.2040-1124.2011.00138.x.

75. Торшин И.Ю., Лила А.М., Наумов А.В. и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2020; 13 (4): 18–29 https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066.

76. Громова О.А., Торшин И.Ю., Зайчик Б.Ц. и др. О различиях в стандартизации лекарственных препаратов на основе экстрактов хондроитина сульфата. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2021; 14 (1): 40–52. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.083.